Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of California, Los Angeles | OTHER |
| Columbia University | OTHER |
| The Cleveland Clinic | OTHER |
| Massachusetts General Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to compare survival of both patients and newly transplanted hearts following heart transplantation among patients who were transplanted with donated hearts preserved on ice and those who were transplanted with donated hearts using the Organ Care System (OCS). The Organ care system preserves the hearts in a warm blood perfused beating state. The study also compares the number of rejection episodes, heart related adverse events, ICU time, and ventilation time between the two groups. The study is considered a success if survival in the OCS group was not inferior to the ice group.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Organ Care System | Experimental |
| |
| Cold cardioplegia solution | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Organ Care System | Device | The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device. |
| Measure | Description | Time Frame |
|---|---|---|
| 30-day patient survival following transplantation with the originally transplanted heart and no mechanical circulatory assist device at day 30 | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of all cardiac graft-related serious adverse events | 30 days | |
| Incidence of biopsy proven ISHLT grade 2R or 3R acute rejection on any of the surveillance endomyocardial biopsies or clinically symptomatic rejection requiring augmentation of immunosuppressive therapy during the 30 day follow up |
Not provided
Inclusion Criteria:
Recipient Day of Transplant
Donor Hearts
Exclusion Criteria:
Recipient Day of Transplant
Donor Hearts
Abnormal coronary angiogram defined as >50% stenosis, requiring coronary bypass
Donor-to-recipient body weight ratio of <0.6
Inotrope support at time of final heart assessment including, but not limited to:
Presence of any exclusion criterion based on the standard practice of the investigational site
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Abbas Ardehali, MD | University of California, Los Angeles | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCLA Medical Center | Los Angeles | California | 90095 | United States | ||
| Cedars-Sinai Medical Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25888086 | Derived | Ardehali A, Esmailian F, Deng M, Soltesz E, Hsich E, Naka Y, Mancini D, Camacho M, Zucker M, Leprince P, Padera R, Kobashigawa J; PROCEED II trial investigators. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. Lancet. 2015 Jun 27;385(9987):2577-84. doi: 10.1016/S0140-6736(15)60261-6. Epub 2015 Apr 14. |
Not provided
Not provided
Not provided
| OTHER |
| Newark Beth Israel Medical Center | OTHER |
| Cedars-Sinai Medical Center | OTHER |
| Groupe Hospitalier Pitie-Salpetriere | OTHER |
| Papworth Hospital NHS Foundation Trust | OTHER_GOV |
| Azienda Ospedaliera S. Maria della Misericordia | OTHER |
| Royal Brompton & Harefield NHS Foundation Trust | OTHER |
| Indiana University | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Cold Cardioplegia Solution | Device | This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital |
|
| 30 day |
| Length of ICU stay | 30 day |
| Los Angeles |
| California |
| 90211 |
| United States |
| Indiana University | Indianapolis | Indiana | 46202 | United States |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
| Newark Beth Israel Medical Center | Newark | New Jersey | 07112 | United States |
| Columbia University Medical Center | New York | New York | 10032 | United States |
| Cleveland Clinic | Cleveland | Ohio | 44195 | United States |
| Hospitalier Pitie-Salpetriere | Paris | 75013 | France |
| Azienda Ospedaliera S. Maria della Misericordia | Udine | 33100 | Italy |
| Papworth Hospital | Cambridge | CB23 3RE | United Kingdom |
| Harefield Hospital | London | United Kingdom |
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided